RISK11 signature scores for the biomarker-guided tuberculosis preventive therapy (CORTIS) randomised controlled trial
datasetposted on 2021-01-15, 09:05 authored by Thomas ScribaThomas Scriba, Andrew Fiore-GartlandAndrew Fiore-Gartland, Adam Penn-Nicholson, Humphrey MulengaHumphrey Mulenga, Stanley KimbungStanley Kimbung, Bhavesh Borate, Simon MendelsohnSimon Mendelsohn, Katie Hadley, Chris Hikuam, Masooda Kaskar, Munyaradzi MusvosviMunyaradzi Musvosvi, Nicole Bilek, Steven Self, Tom Sumner, Richard White, Mzwandile Erasmus, Lungisa Jaxa, Rodney Raphela, Craig Innes, William Brumskine, Andriëtte Hiemstra, Stephanus T. Malherbe, Razia Hassan-Moosa, Michèle Tameris, Gerhard Walzl, Kogieleum Naidoo, Gavin Churchyard, Mark Hatherill
RISK11 transcriptomic signature scores for 20,207 volunteers who were screened at five geographically diverse sites across South Africa. Signature scores were computed from QC'ed gene expression measurements performed by microfluidic RT-qPCR on mRNA derived from whole blood collected in PAXgene tubes. Participants were randomised into three groups and followed-up for 15 months to evaluate diagnostic and prognostic performance of RISK11 and to evaluate efficacy of high-dose isoniazid and rifapentine for prevention of incident TB.